

GenepoweRx and MGI Tech to accelerate Al-driven genomic solutions in personalised medicine

11 June 2025 | News

GenepoweRx and MGI will integrate their respective strengths in genomics, bioinformatics, and AI



Indian startup GenepoweRx, a trailblazer in artificial intelligence (AI)-powered personalised medicine based on genomic insights, has announced a strategic collaboration with China-based MGI Tech Co., a company dedicated to developing core tools and technologies that drive innovation in life sciences.

This partnership aims to revolutionise the landscape of predictive healthcare, precision medicine, and longevity science through cutting-edge sequencing and AI-powered analytics.

With a shared vision to make personalised, preventive healthcare more accessible and effective, GenepoweRx and MGI will integrate their respective strengths in genomics, bioinformatics, and AI to deliver rapid, clinical-grade genomic services to individuals and institutions worldwide.

"Our collaboration with MGI is a game-changer for personalised medicine," said Dr Kalyan Ram Uppaluri, Founder of GenepoweRx.

"By combining MGI's robust sequencing platforms with our AI-driven insights engine, we are poised to offer unparalleled turnaround times, accuracy, and depth of interpretation. Together, we aim to empower individuals with timely, personalised, and preventive healthcare solutions", said Dr Hima Jyothi Challa, MD, GenepoweRx.

Roy Tan, General Manager of MGI Asia Pacific, stated, "We are excited to contribute to personalised medicine through joint efforts with GenepoweRx. By integrating our advanced genomic technologies with GenepoweRx's innovative Al-driven analytics, we aim to not only strengthen GenepoweRx's genomic offerings but also empower healthcare providers and patients alike. This collaboration marks a significant step toward a future where personalised and preventive healthcare is not just a promise but a reality for everyone."